- Home
- DKL vs APLS Comparison
DKL vs APLS Comparison
Compare DKL & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKL
- APLS
- Stock Information
- Founded
- DKL 2012
- APLS 2009
- Country
- DKL United States
- APLS United States
- Employees
- DKL N/A
- APLS N/A
- Industry
- DKL Natural Gas Distribution
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- DKL Energy
- APLS Health Care
- Exchange
- DKL Nasdaq
- APLS Nasdaq
- Market Cap
- DKL 2.3B
- APLS 2.2B
- IPO Year
- DKL N/A
- APLS 2017
- Fundamental
- Price
- DKL $43.74
- APLS $18.25
- Analyst Decision
- DKL Buy
- APLS Buy
- Analyst Count
- DKL 4
- APLS 19
- Target Price
- DKL $44.25
- APLS $37.39
- AVG Volume (30 Days)
- DKL 96.4K
- APLS 1.9M
- Earning Date
- DKL 08-05-2025
- APLS 07-31-2025
- Dividend Yield
- DKL 10.15%
- APLS N/A
- EPS Growth
- DKL 7.97
- APLS N/A
- EPS
- DKL 2.98
- APLS N/A
- Revenue
- DKL $938,491,000.00
- APLS $775,839,000.00
- Revenue This Year
- DKL $21.19
- APLS $1.01
- Revenue Next Year
- DKL N/A
- APLS $22.14
- P/E Ratio
- DKL $14.67
- APLS N/A
- Revenue Growth
- DKL N/A
- APLS 48.04
- 52 Week Low
- DKL $34.59
- APLS $16.10
- 52 Week High
- DKL $45.71
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- DKL 61.82
- APLS 48.67
- Support Level
- DKL $42.29
- APLS $17.15
- Resistance Level
- DKL $43.83
- APLS $18.60
- Average True Range (ATR)
- DKL 0.91
- APLS 0.70
- MACD
- DKL -0.05
- APLS -0.04
- Stochastic Oscillator
- DKL 81.31
- APLS 45.25
About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.